Gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric IBD patients
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0311604 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Katrine Carlsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Adolescence, Copenhagen University Hospital-Amager Hvidovre Hospital, Hvidovre, Denmark. Hauptthemen laut MEDLINE: Infliximab, Gastrointestinal Microbiome, Feces. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Louis-Hansens Foundation, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Background
The gut microbiome plays a crucial role in the pathogenesis and progression of inflammatory bowel disease (IBD). Understanding the dynamics of the gut microbiome in relation to treatment can provide valuable insights into disease management and therapy strategies. The aim of this study is to investigate if diversity and composition of the gut microbiome correlate with time since treatment and disease activity during maintenance infliximab (IFX) therapy among children with IBD.
Methods
Data was collected from IBD patients aged 10–17 participating in an IFX-eHealth study. IFX infusions were administered in 4–12-week intervals based on weekly faecal calprotectin (FC) combined with symptom scores. Excess stool samples underwent microbiome profiling using 16S rRNA gene sequencing. Microbiome features, including alpha diversity and single taxa, were analysed for three key variables: 1) weeks-since-treatment, 2) FC, and 3) symptom score.
Results
From 25 patients (median age 14.4 years) diagnosed with Crohn´s Disease (n = 16) or ulcerative colitis (n = 9), microbiota were analysed in 671 faecal samples collected across 15 treatment intervals. A significant decrease over time in Shannon diversity, following the initial increase within four weeks of treatment, was found across patients. FC levels showed no association with alpha diversity ( p >0.1), while symptom scores showed a negative association with Shannon and observed diversity in patients with UC. At the genus level, a lower abundance of the genera Anaerostipes and Fusicatenibacter (Firmicutes), and a greater abundance of the genus Parasutterella (Proteobacteria), were associated ( p .adj
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics and Adolescence, Copenhagen University Hospital-Amager Hvidovre Hospital, Hvidovre, Denmark.
- Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescent and Adults, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre, Denmark.
- Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
- Institut für Medizinische Informatik und Statistik, Universitätsklinikum Schleswig-Holstein, Christian-Albrechts-Universität zu Kiel, Kiel, Germany.
ORCID-Profile: Louise B Thingholm, Mikkel Malham
Förderung
- Louis-Hansens Foundation
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Carlsen, K., Thingholm, L. B., Dempfle, A., Malham, M., Bang, C., Franke, A., & Wewer, V. (2024). Gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric IBD patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0311604
Vancouver
Carlsen K, Thingholm LB, Dempfle A, Malham M, Bang C, Franke A, et al. Gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric IBD patients. PLOS ONE. 2024. doi:10.1371/journal.pone.0311604
BibTeX
@article{Carlsen2024,
author = {Carlsen, Katrine and Thingholm, Louise B and Dempfle, Astrid and Malham, Mikkel and Bang, Corinna and Franke, Andre and Wewer, Vibeke},
title = {Gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric IBD patients},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0311604}
}
EUVIMED